Table 1.
Pre-HCT | Pre-HCT | 3 months post HCT | 6 months post HCT | 7.5 months post HCT | 8.5 months post HCT | 12 months post HCT | 16 months post HCT | 2 years post HCT | |
---|---|---|---|---|---|---|---|---|---|
Age of the patient at analysis | DOL 5 | 2 months | 5 months | 8 months | 9.5 months | 10.5 months | 14 months | 18 months | 27–28 months |
ANC/uL | 1,600 | 200 | 4,940 | 1,020 | 396* | 310* | 320* | 3,630* | 670 |
ALC/uL | 200 | 536 | 810 | 156 | 382 | 640 | 1,620 | 1,650 | 1,460 |
CD3+/ul | 41 | 175 | 55 | 77 | 184 | 421 | 1,281 | 1,524 | 1,172 |
CD4+/uL | 28 | 48 | 5 | 12 | 84 | 135 | 282 | 413 | |
CD8+/uL | 11 | 123 | 36 | 50 | 81 | 241 | 847 | 694 | |
CD4+/CD45RA+ (%) | 5.7 | 0.4 | 2.9 | 9.5 | 10.6 | 6.2 | 11.7 | ||
CD4+/CD45RO+ (%) | 5.4 | 0.6 | 5.7 | 10.2 | 9.9 | 10.9 | 16.1 | ||
Mitogens (PHA) % of control CPM | 2% CPM 887 | < 1% CPM 1,127 | 1% CPM 2,439 | ||||||
TRECS*** | 1,398 | 2,283 | 2,962 | ||||||
CD19+ B cells/uL | 3 | 255 | 704 | 46 | 167 | 84 | 86 | 91 | |
NK cells/uL | 78 | 110 | 51 | 32 | 36 | 141 | 245 | 164 | |
Chimerism∧∧ | 82% | 26% | 25% | 26% | 41% | ||||
Chimerism (CD3) | 57% | 36% | 76% | 83% | 83% | ||||
Chimerism (CD19) | 96% | 49% | 15% | ||||||
Chimerism (NK) | 96% | 70% | |||||||
Chimerism (Myeloid) | 79% | 17% | 2% |
, on G-CSF supplementation;
, Count per 106 CD3 cells;
, Unenriched whole blood.